ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. senior vice president of generics Ori Gutwerg reported a sale of 3,162 shares of common stock on 2026-08-10 at $77.00 per share in an open market or private transaction. After this sale, he directly holds 75,534 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 3,162 shares

Net Sell 1 txn

Insider Gutwerg Ori

Role SVP, GENERICS

Sold 3,162 shs ($243K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,162	$77.00	$243K

Holdings After Transaction: Common Stock — 75,534 shares (Direct)

Key Figures

Shares sold: 3,162 shares Sale price per share: $77.00 Shares held after transaction: 75,534 shares +1 more

4 metrics

Shares sold 3,162 shares Common stock sale reported on 2026-08-10

Sale price per share $77.00 Per-share price for the 3,162 shares of common stock sold

Shares held after transaction 75,534 shares Direct ownership of ANI Pharmaceuticals common stock following the sale

Net shares sold 3,162 shares Net-sell direction in transaction summary

Key Terms

open market or private transaction, Common Stock, direct ownership

3 terms

open market or private transaction financial

"Sale in open market or private transaction"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"ownership_type: direct"

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Ori Gutwerg?

ANI Pharmaceuticals reported that SVP, Generics Ori Gutwerg sold 3,162 shares of common stock on 2026-08-10. The transaction was reported as a sale in an open market or private transaction at $77.00 per share.

At what price did Ori Gutwerg sell ANI Pharmaceuticals (ANIP) shares?

Ori Gutwerg sold ANI Pharmaceuticals common stock at $77.00 per share. The Form 4 identifies this as the per-share transaction price for the 3,162 shares sold on 2026-08-10 in an open market or private transaction.

How many ANI Pharmaceuticals (ANIP) shares does Ori Gutwerg hold after this sale?

Following the reported sale, Ori Gutwerg directly holds 75,534 shares of ANI Pharmaceuticals common stock. This post-transaction holding is disclosed in the Form 4 as the total shares following the transaction.

Was the ANI Pharmaceuticals (ANIP) insider sale under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not affirmatively marked, and there is no footnote describing a trading plan. The transaction is therefore not identified in the filing as being executed under a Rule 10b5-1 plan.

What is Ori Gutwerg’s role at ANI Pharmaceuticals (ANIP)?

Ori Gutwerg is reported as an officer of ANI Pharmaceuticals with the title SVP, GENERICS. His position and title are disclosed in the Form 4 reporting the sale of 3,162 shares of company common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 08:57 PM Accepted by SEC EDGAR 08/11/2026 - 08:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S		3,162	D	$77	75,534	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)